(Q34716590)

4 August 2017

title

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer (English)

1 reference

4 August 2017

main subject

phase III clinical trial

0 references

1 reference

6

Claudine Isaacs

1 reference

4 August 2017

George T Budd

1

1 reference

4 August 2017

William E Barlow

2

1 reference

4 August 2017

Halle C F Moore

3

1 reference

4 August 2017

Timothy J Hobday

4

1 reference

4 August 2017

James A Stewart

5

1 reference

4 August 2017

Muhammad Salim

7

1 reference

4 August 2017

Jonathan K Cho

8

1 reference

4 August 2017

Kristine J Rinn

9

1 reference

4 August 2017

Kathy S Albain

10

1 reference

4 August 2017

Helen K Chew

11

1 reference

4 August 2017

Gary V Burton

12

1 reference

4 August 2017

Timothy D Moore

13

1 reference

4 August 2017

Gordan Srkalovic

14

1 reference

4 August 2017

Bradley A McGregor

15

1 reference

4 August 2017

Lawrence E Flaherty

16

1 reference

4 August 2017

Robert B Livingston

17

1 reference

4 August 2017

Danika L Lew

18

1 reference

4 August 2017

Julie R Gralow

19

1 reference

4 August 2017

Gabriel N Hortobagyi

20

1 reference

4 August 2017

language of work or name

English

0 references

publication date

24 November 2014

1 reference

Journal of Clinical Oncology

4 August 2017

published in

1 reference

4 August 2017

volume

33

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

58-64

1 reference

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Adjuvant chemotherapy in older women with early-stage breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Weekly paclitaxel in the adjuvant treatment of breast cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Group sequential procedures: calendar versus information time

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Risk factors for doxorubicin-induced congestive heart failure

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Dose-dense anthracycline-based chemotherapy for node-positive breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

9 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4268253

9 December 2018

Identifiers

DOI

10.1200/JCO.2014.56.3296

1 reference

4 August 2017

1 reference

4 August 2017

1 reference